Trifluridine/Tipiracil Hydrochloride

DRUG2 trials

Sponsors

Dominik Paul Modest, Sir Run Run Shaw Hospital

Conditions

Metastatic Colorectal CancerRectal Adenocarcinoma

Phase 2

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

RecruitingNCT05007132

Dominik Paul ModestMetastatic Colorectal Cancer

Start: 2021-12-17End: 2032-12-31Target: 153Updated: 2024-02-15

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Not yet recruitingNCT06872606

Sir Run Run Shaw HospitalRectal Adenocarcinoma

Start: 2025-04-01End: 2028-04-01Target: 33Updated: 2025-03-12

Related Papers

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.

2022-07-274 citations